Insights, Not Hunches

Log in Or Sign up!

"Using Clinicopathologic Markers in Patients with Non–Small-Cell Lung Cancer: A Pathologist’s Perspective" by Peter Illei

Enroll now for FREE

  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0

Using Clinicopathologic Markers in Patients with Non–Small-Cell Lung Cancer:
A Pathologist’s Perspective

created on: 04/01/11

This activity is presented by the Johns Hopkins University School of Medicine.

Supported by educational grants from Bristol-Myers Squibb Company, Genentech, Inc, and OSI Pharmaceuticals Inc.

Please click "enroll now" to begin course.

OVERVIEW
In the United States, lung cancer remains the leading cause of cancer mortality in both men and women, with more than 50% of patients presenting with locally advanced, inoperable, or metastatic disease. Approximately 33% of patients with non–small-cell lung cancer (NSCLC) present with advanced-stage disease while most patients with early stage NSCLC will eventually develop metastatic lung cancer. Despite the numerous therapeutic options available, only 15% of patients with lung cancer survive beyond 5 years from diagnosis. Recent advances in genetic and histological markers, coupled with emerging targeted agents for NSCLC, have the potential to improve patient outcomes. The following educational activity uses a series of case-based and knowledge questions to discuss the prognostic and predictive role of histologic and immunohistochemical markers in NSCLC therapy, the evaluation of current and emerging therapeutic strategies, and methods for recognizing how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC and improve outcomes.

GOAL
This educational activity will provide anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists, with up-to-date information about using clinicopathologic markers in patients with NSCLC.

INTENDED AUDIENCE
This activity is designed for anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists. No prerequisites required.

LEARNING OBJECTIVE
Upon the conclusion of this activity, the participant should be able to:

  • Describe the prognostic and predictive role of histologic and immunohistochemical markers in NSCLC therapy.
  • Evaluate current and emerging therapeutic strategies that incorporate targeted agents with chemotherapy for patients with advanced NSCLC based on tumor biology.
  • Recognize how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Johns Hopkins University School of Medicine is a provider for Self-Assessment Modules as defined by the American Board of Pathology, and has designated this educational activity for a maximum of 2.0 SAM credits.

The estimated time to complete this activity: 2 hours.

Release date: August 15, 2011. Expiration date: August 15, 2012.

HOW TO RECEIVE CREDIT OR CONTACT HOURS
The following SpacedEd module consists of 20 questions that will be sent to you on a regular schedule via email, the Web, or RSS. They can be accessed from a desktop browser or a mobile device such as an iPhone or BlackBerry. The sequence of questions will adapt based on your answers. Questions are retired after 2 correct responses. All 20 questions must be retired to receive CME credit. A certificate of participation will be available online immediately following successful completion of the course.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Chair and Planner
illei photoPeter B. Illei, MD
Assistant Professor of Pathology
Director of Immunopathology Laboratory
Johns Hopkins Medical Institutions
Baltimore, Maryland

 

 

Participating Faculty/Authors
created on: 07/12/11Andre Luis Moreira, MD, PhD (Planner)

Associate Attending Pathologist
Memorial Sloan-Kettering Cancer Center
New York, New York

 

 

Participating Faculty Disclosures
No speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Planner Disclosures
No planner has indicated that they have any financial interests or relationships with a commercial entity.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION
No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing names implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. CME at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/2000/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

  • Published 08/15/11
  • Learners 89
  • Views 1129
  • Questions 20

Course Details

This activity is designed for anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists. No prerequisites required.

Reviews

Darryl Carter
  • Your rating: 1 out of 5
  • 1
  • 1
  • 1
  • 1
  • 1

by Darryl Carter on 09/20/11

The questions are utilizing proposed criteria for diagnosis and staging rather than WHO criteria, which have been established for several years. It is likely that the proposed criteria are an advance in understanding adenocarcinomas of the lung and especially in their staging, but they have not yet been formally adopted by any body other than IASLC. I suggest that 2 answers be offered – current WHO classification and proposed IASLC classification.

Jane  Lysko
  • Your rating: 1 out of 5
  • 1
  • 1
  • 1
  • 1
  • 1

by Jane Lysko on 11/09/11

moon-woo nam
  • Your rating: 4 out of 5
  • 4
  • 4
  • 4
  • 4
  • 4

by moon-woo nam on 11/10/11

Good, short review
Anyway the classifications will keep changing forever and what you choose to use is up to you and your clinicians.

shaza atassi
  • Your rating: 5 out of 5
  • 5
  • 5
  • 5
  • 5
  • 5

by shaza atassi on 12/17/11

Read all reviews

Recent Reviews

  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
Published 09/01/12 by irena sheyn
  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
Published 10/12/12 by Chi-Bao Bui
  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
Published 08/06/12 by ramona cioroboreanu
  • Global rating average: 3.0 out of 5
  • 3.0
  • 3.0
  • 3.0
  • 3.0
  • 3.0
Excellent course for upgradation of knowledge about pulmonary neoplasms in pathological and clinical prospective
Published 06/18/12 by SHASHIKANT Adlekha

Read all reviews

About Peter Illei

pillei
  • Peter Illei
  • Member since 06/07/2011
  • Published Courses: one

Peter B. Illei, MD, is an Assistant Professor of Pathology and the Director of Immunopathology Laboratory at Johns Hopkins Medical Institutions in Baltimore, Maryland. Dr Illei obtained his medical degree at the University of Pécs Medical School in Pécs, Hungary. He completed his residency in anatomic and clinical pathology at New York University Medical Center in New York City, New York in 1998, and his fellowship in Oncologic Surgical Pathology and Cytopathology at the Memorial Sloan-Kettering Cancer Center in New York City in 2000. He is certified in anatomic pathology, cytopathology, and clinical pathology by the American Board of Pathology and is a member of the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the US-Canadian Academy of Pathology, and the College of American Pathologists.

Dr Illei’s research interests range from the development of novel immunohistochemical and molecular markers for the diagnosis of solid tissue tumors, the pathology of lung cancer and lung transplantation, and thymic neoplasms. His research endeavors include immunohistochemical and molecular characterization of lung cancers, the development of novel tests for accurate typing of non–small-cell lung cancer, as well as the discovery of new prognostic and therapeutic markers, the role of antibody mediated rejection in lung transplants, the immunohistochemical profiling of thymic epithelial neoplasms, and the role of rapid tissue processing and rapid automated immunohistochemistry in large tertiary care facilities. Dr Illei received the Pulmonary Pathology Society First Prize at the 91st Annual Meeting of the US and Canadian Academy of Pathology in Chicago, Illinois on February 25, 2002. In addition, he also won a Poster Award at the International Congress of the International Academy of Pathology in October 2006 in Budapest, Hungary. He has contributed to many notable clinical journals including the American Journal of Surgical Pathology, Cancer Biology & Therapy, and Clinical Cancer Research

View full profile